#Hong Kong #DAXXIFY #Sisram Medical #Alma Harmony

Sisram Medical Reports Robust Growth for 2025

Sisram Medical Ltd, a global leader in medical aesthetic solutions, has recently announced its remarkable annual results for the year ending December 31, 2025. This report highlights a steady growth trajectory across various sectors, confirming the effectiveness of the company's strategic initiatives.

Financial Performance Overview

The company's consolidated revenue for 2025 reached approximately US$365.3 million, reflecting a 4.7% increase compared to the previous year. Notably, the injectables division reported an impressive boost, with revenues surging by 185.6% year-on-year, totaling US$28.0 million. This growth underscores the rising demand for injectable solutions in various global markets.

International Market Dynamics

Sisram Medical has seen significant growth in international markets, excluding North America, which recorded a 20.1% increase year-over-year. The Asia-Pacific region emerged as the largest revenue contributor, boasting a growth of 26.9% to US$147.4 million, accounting for 40.4% of the total revenue. Meanwhile, Europe and the Middle East/Africa regions also experienced healthy performance, with respective revenues of US$56.4 million and US$36.4 million. Contrarily, North American revenue declined by 19.2%, prompting the company to reassess its strategies in that market.

Strategic Innovations and Product Launches

In response to shifting market demands, Sisram Medical continued to enhance its product portfolio with innovative solutions. Noteworthy achievements include the successful introduction of DAXXIFY in Mainland China, which achieved regulatory approval and has seen substantial adoption across various provinces, with over 10,000 units shipped.

Furthermore, Profhilo continued to gain traction in Thailand, while Revanesse showed strong performance in the UK, highlighting growing acceptance of Sisram’s products among practitioners. The company also expanded its offerings with Hallura, a next-generation hyaluronic acid filler, launched successfully in Israel.

Building an Aesthetics Ecosystem

As part of its comprehensive strategy, Sisram Medical is working diligently to create an integrated aesthetics ecosystem, enhancing patient care through innovative technology. One of the key developments is Universkin by Alma, an AI-driven skincare platform that provides tailored formulas based on advanced skin analysis. This technology aims to improve patient outcomes and elevate daily skincare routines.

Additionally, Alma IQ™, developed in collaboration with Sylton, offers advanced imaging and diagnostic capabilities, allowing for more accurate treatment planning.

Future Outlook

Looking ahead, Sisram is entering a crucial phase focusing on bolstering its integrated aesthetics ecosystem. Plans are in place to establish a manufacturing facility in China which will enhance regional R&D and production capabilities. The company is prioritizing the commercialization of DAXXIFY in China and advancing regulatory submissions for additional injectable products.

Furthermore, Sisram aims to expand the adoption of Alma Harmony and strengthen its AI-driven platforms in diagnostics and personalized treatments. The company is also exploring strategic mergers and acquisitions to enhance its innovation capabilities and product portfolio.

Management Perspectives

Executives at Sisram are optimistic about the future, with Chairman Mr. Lior Moshe Dayan emphasizing the long-term growth potential of the medical aesthetics industry. Expectations of increased patient awareness and treatment adoption drives Sisram's commitment to developing an integrated ecosystem of devices and healthcare solutions.

CEO Mr. Eyal Ben David noted the solid demand for the company's offerings and the confidence that practitioners are showing in Sisram's integrated aesthetic solutions. The strategic advancements made during 2025 have laid a robust foundation for the future.

Co-CEO and CFO Mr. Jiahong Li reiterated Sisram’s commitment to recalibrating amidst external challenges, boasting year-on-year revenue growth supported by prudent cost management. The company looks forward to subsequent investments in core and emerging growth areas to secure sustained value creation for stakeholders.

Conclusion

In summary, Sisram Medical’s impressive growth in 2025 encapsulates a proactive response to market shifts and robust operational performance. As the medical aesthetics sector continues to burgeon, Sisram is well-positioned to lead due to its strong product portfolio and innovative approach to client care.